DEFA14A: Lineage Cell Therapeutics to Hold Annual Shareholder Meeting on June 11, 2024
Proxy Statement
Lineage Cell Therapeutics will hold its annual shareholder meeting on June 11, 2024, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.
Summary
- Lineage Cell Therapeutics, Inc. is holding its annual meeting of shareholders on June 11, 2024.
- Shareholders of record as of April 19, 2024, are eligible to vote.
- The meeting will include the election of eight directors to hold office until the 2025 annual meeting.
- Shareholders will also vote to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- An advisory vote will be held to approve the compensation paid to the named executive officers.
- The board of directors recommends voting for each nominee listed in Proposals 1 and for Proposals 2 and 3.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment as it reflects normal corporate operations and governance.
Positives
- The company is adhering to corporate governance practices by holding an annual shareholder meeting.
- Shareholders have the opportunity to vote on key decisions, including the election of directors and the ratification of the accounting firm.
Future Outlook
The document outlines the agenda for the upcoming annual meeting, focusing on standard corporate governance matters.
Industry Context
This announcement is a routine part of corporate governance, ensuring shareholders have a voice in key company decisions, which is standard practice across the industry.
Stakeholder Impact
- Shareholders have the opportunity to influence the company's direction through voting.
- The outcome of the votes will impact the composition of the board and the selection of the accounting firm.
Next Steps
- Shareholders should review the proxy materials and vote on the proposals.
- The company will proceed with the annual meeting on June 11, 2024.
Key Dates
| Date | Description |
|---|---|
| April 19, 2024 | Shareholders of record date for the annual meeting. |
| May 31, 2024 | Deadline to request paper copies of proxy materials in time for the meeting. |
| June 11, 2024 | Date of the Annual Meeting of Shareholders. |
| December 31, 2024 | Fiscal year end for which WithumSmith+Brown, PC is proposed as the accounting firm. |
| 2025 | Next annual meeting of shareholders. |
Keywords
Annual Meeting, Shareholders, Proxy Statement, Lineage Cell Therapeutics, Directors, Executive Compensation, Accounting Firm, Voting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.